Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.

ABSTRACT:

Background

International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium (IMDC) risk groups are important when considering therapeutic options for first-line treatment.

Materials and methods

Adult patients with clear cell mRCC initiating first-line sunitinib between 2010 and 2018 were included in this retrospective database study. Median time to treatment discontinuation (TTD) and overall survival (OS) were estimated using Kaplan-Meier analysis. Outcomes were stratified by IMDC risk groups and evaluated for those in the combined intermediate and poor risk group and separately for those in the intermediate risk group with one versus two risk factors.

Results

Among 1,769 patients treated with first-line sunitinib, 318 (18%) had favorable, 1,031 (58%) had inte

SUBMITTER: Savard MF 

PROVIDER: S-EPMC7216460 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature